Altimmune, Inc. (ALT) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Philadelphia, Pennsylvania--(Newsfile Corp. - August 22, 2025) - Berger Montague PC is investigating claims under the federal securities laws against Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) after a class action lawsuit was filed against Altimmune.

Investor Deadline: Investors who purchased or acquired Altimmune securities between August 10, 2023 through June 25, 2025 (the "Class Period") may, no later than October 6, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

On June 26, 2025, Altimmune issued a press release announcing topline results from its IMPACT Phase 2b trial of Pemvidutide for the treatment of MASH. Despite management's repeated positive statements ahead of the results, the Company revealed a failure to achieve statistical significance in the fibrosis reduction primary endpoint, citing a higher-than-expected placebo response. While a positive trend was observed, this key metric fell short. When asked about the failure, the Company's executives attributed the shortcoming to the trial's Phase 2 nature and expressed optimism about the Phase 3 trial instead.

In reaction to this news, Altimmune's stock price plunged from a close of $7.71 on June 25, 2025, to a close of $3.61 on June 26 - a one-day decline of more than 53% in a single day.

If you are an Altimmune investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.

About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263492